Synthesis and biological activity of a focused library of mitogen-activated protein kinase phosphatase inhibitors

被引:16
作者
Arnold, David M.
Foster, Caleb
Huryn, Donna M.
Lazo, John S.
Johnston, Paul A.
Wipf, Peter [1 ]
机构
[1] Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA
[2] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA
[3] Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA
[4] Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15260 USA
[5] Univ Pittsburgh, Pittsburgh Mol Lib Screening Ctr, Pittsburgh, PA 15260 USA
关键词
dual-specificity phosphatase; inhibitor synthesis; library synthesis; mitogen-activated protein kinase phosphatase-1; Molecular Libraries Screening Center Network; PubChem; quinolines; uracils;
D O I
10.1111/j.1747-0285.2007.00474.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mitogen-activated protein kinase phosphatase 1 is a tyrosine phosphatase superfamily member that dephosphorylates and inactivates mitogen-activated protein kinase substrates, such as p38, c-Jun-N-terminal kinase, and extracellular signal-related kinase. These mitogen-activated protein kinase substrates regulate many cellular processes associated with human diseases. In spite of this potential as a molecular target for chemotherapy, however, pharmacologically tractable inhibitors of mitogen-activated protein kinase phosphatase-1 have yet to be developed. Based on the results from a high-throughput screen for small molecule inhibitors of mitogen-activated protein kinase phosphatase-1, we designed, synthesized, and evaluated a focused library in an effort to further understand the structural requirements for mitogen-activated protein kinase phosphatase-1 inhibitory activity.
引用
收藏
页码:23 / 30
页数:8
相关论文
共 16 条
[1]   MAPK-specific tyrosine phosphatases: new targets for drug discovery? [J].
Barr, Alastair J. ;
Knapp, Stefan .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2006, 27 (10) :525-530
[2]   Mammalian MAP kinase signalling cascades [J].
Chang, LF ;
Karin, M .
NATURE, 2001, 410 (6824) :37-40
[3]   PICORNAVIRUS INHIBITORS - TRIFLUOROMETHYL SUBSTITUTION PROVIDES A GLOBAL PROTECTIVE EFFECT AGAINST HEPATIC-METABOLISM [J].
DIANA, GD ;
RUDEWICZ, P ;
PEVEAR, DC ;
NITZ, TJ ;
ALDOUS, SC ;
ALDOUS, DJ ;
ROBINSON, DT ;
DRAPER, T ;
DUTKO, FJ ;
ALDI, C ;
GENDRON, G ;
OGLESBY, RC ;
VOLKOTS, DL ;
REUMAN, M ;
BAILEY, TR ;
CZERNIAK, R ;
BLOCK, T ;
ROLAND, R ;
OPPERMANN, J .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (08) :1355-1371
[4]   Dual specificity protein phosphatases: Therapeutic targets for cancer and Alzheimer's disease [J].
Ducruet, AP ;
Vogt, A ;
Wipf, P ;
Lazo, JS .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2005, 45 :725-750
[5]   Solution structure of the MAPK phosphatase PAC-1 catalytic domain: Insights into substrate-induced enzymatic activation of MKP [J].
Farooq, A ;
Plotnikova, O ;
Chaturvedi, G ;
Yan, S ;
Zeng, L ;
Zhang, O ;
Zhou, MM .
STRUCTURE, 2003, 11 (02) :155-164
[6]   Glucocorticoids inhibit lung cancer cell growth through both the extracellular signal-related kinase pathway and cell cycle regulators [J].
Greenberg, AK ;
Hu, J ;
Basu, S ;
Hay, J ;
Reibman, J ;
Yie, TA ;
Tchou-Wong, KM ;
Rom, WN ;
Lee, TC .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2002, 27 (03) :320-328
[7]   Synthesis and preliminary evaluation of new 5-pyrazolinone derivatives as analgesic agents [J].
Gürsoy, A ;
Demirayak, S ;
Çapan, G ;
Erol, K ;
Vural, K .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2000, 35 (03) :359-364
[8]   The carboxyl-terminal domains of MKP-1 and MKP-2 have inhibitory effects on their phosphatase activity [J].
Hutter, D ;
Chen, PL ;
Barnes, J ;
Liu, YS .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2002, 233 (1-2) :107-117
[9]   Crystal structure of the catalytic domain of human MAP kinase phosphatase 5: Structural insight into constitutively active phosphatase [J].
Jeong, Dae Gwin ;
Yoon, Tae-Sung ;
Kim, Jae Hoon ;
Shim, Mi Young ;
Jung, Suk-Kyeong ;
Son, Jeong Hee ;
Ryu, Seong Eon ;
Kim, Seung Jun .
JOURNAL OF MOLECULAR BIOLOGY, 2006, 360 (05) :946-955
[10]   Protein tyrosine phosphatase 1B inhibitors for diabetes [J].
Johnson, TO ;
Ermolieff, J ;
Jirousek, MR .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (09) :696-709